Sanofi (NASDAQ:SNY) Rating Lowered to Hold at Wall Street Zen

Sanofi (NASDAQ:SNY) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Several other equities analysts have also commented on SNY. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Morgan Stanley set a $49.00 price objective on shares of Sanofi in a research report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $49.50.

Sanofi Trading Up 1.0%

Shares of SNY stock opened at $44.66 on Friday. The stock has a market cap of $108.28 billion, a P/E ratio of 12.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.34. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The stock has a 50 day simple moving average of $43.35 and a 200 day simple moving average of $45.52.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SNY. Fiduciary Financial Group LLC lifted its holdings in shares of Sanofi by 33.8% in the second quarter. Fiduciary Financial Group LLC now owns 8,403 shares of the company’s stock worth $358,000 after acquiring an additional 2,124 shares during the last quarter. Fulton Bank N.A. grew its holdings in shares of Sanofi by 5.6% during the 2nd quarter. Fulton Bank N.A. now owns 68,196 shares of the company’s stock valued at $2,909,000 after purchasing an additional 3,623 shares during the last quarter. First Bank & Trust grew its holdings in shares of Sanofi by 23.4% during the 2nd quarter. First Bank & Trust now owns 83,933 shares of the company’s stock valued at $3,581,000 after purchasing an additional 15,937 shares during the last quarter. Focus Financial Network Inc. increased its position in Sanofi by 9.2% during the 2nd quarter. Focus Financial Network Inc. now owns 5,302 shares of the company’s stock worth $226,000 after purchasing an additional 446 shares in the last quarter. Finally, Valeo Financial Advisors LLC increased its position in Sanofi by 11.0% during the 2nd quarter. Valeo Financial Advisors LLC now owns 5,730 shares of the company’s stock worth $244,000 after purchasing an additional 568 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.